A passionate advocate of healthcare and life sciences innovation, Mark has devoted his career to improving population health and patient outcomes. Mark was previously CEO of Genos, a healthcare big data company (which he co-founded and which was acquired in 2017), CEO of Relevare Pharmaceuticals (a drug development pharmaceutical company based in San Francisco and Australia), and Founder and COO of Hyperion Therapeutics (NASDAQ: HPTX; acquired in 2015). Mark began his career in the Office of Science & Technology at SmithKline Beecham, where he was involved in the creation and development of new business ventures, and at Orchid Biosciences (NASDAQ: ORCH), where he helped lead the company’s successful turnaround.
Mark received a JD from Stanford Law School, an MSc (Economics) from the London School of Economics, and a BA in Human Biology from Stanford University. He is a Member of the Council on Foreign Relations.
Lauren Chazal has a strong command of the clinical trials industry from a site operations, business development and financial management perspective. She began her career in clinical trial operations with a privately-held multi-site clinical research organization. Since 2012, she has held a pivotal role in business development and relationship management for clinical research sites globally. Lauren has in-depth knowledge of the complex interactions between clinical research centers, CROs and sponsors combined with a keen understanding of the importance of access to high quality trial sites and patient recruitment solutions.
Lauren graduated from Lehigh University with a bachelor's degree in Finance and Marketing and from the University of Florida with a Master's in Business Administration. Lauren is a current member of the Healthcare Businesswomen’s Association (HBA).
Cathy Collins brings over 29 years of clinical trial experience to the Headlands team. Her background includes extensive de novo site development (Clinical Studies, LTD and Meridien) as well as site PE backed acquisition/integration (Protocare trials). She is the former owner/CEO of Meridien Research a 5 site, dedicated site organization and Insearch, a business development provider which were both sold to private equity (2012). Prior to joining the Headlands team, Cathy has served as the President and CEO of Clinical Consulting Solutions (CCS), a full-service clinical trials consulting firm providing consulting services spanning new site start-up, therapeutic development, financial/process improvement, and pre-acquisition PE due diligence (2014).
Cathy hold Bachelors and Master’s degrees in nursing and is a 2015 graduate of the Harvard Business School OPM program. She serves on a number of boards in her community including the Bank of Tampa and University of Tampa.
Carole Coplan joined Headlands Research to lead the legal and administrative functions. She brings over 15 years of extensive legal and business development experience to the team. She is the former general manager of Fenwick & West LLP’s FLEX by Fenwick consulting unit, growing a team of in-house attorneys deployed in a number of industries, including healthcare, biotech and high tech industries. She served as the general counsel and corporate secretary of Responsys (later acquired by Oracle) and was the VP of Business Development of Cryptography Research (acquired by Rambus). She has deep transactions and general legal and operational experience that make her an ideal fit for Headlands Research as it scales and grows.
Carole has a Juris Doctor degree from San Francisco Law School and a bachelor’s degree from the University of Florida in political science.
McKenzie Finch possesses a deep understanding of clinical research through her years of experience representing sites within the US and internationally. McKenzie understands the importance of clinical trials and how site networks play an integral role in expediting the drug development process. McKenzie has worked for several site organizations, including Bioclinica and Wake Research, over the past decade and understands the importance of strong collaborative Industry relationships that benefit patients. McKenzie is located in Raleigh, NC.
McKenzie graduated from East Carolina University with a B.S. in Biology.
Hank Heller joined Headlands Research to lead budget and contract negotiations and project manage the implementation of new technological solutions. Hank previously was the Corporate Director of Strategic Operations for a multi-center PE owned research network. Hank started his clinical research career as a Regulatory Specialist for Compass Research and has held multiple positions in site operations, including Operations Coordinator for the Compass Phase I unit, Business Analyst for Bioclinica Research, and Site Director for Meridien Research. Hank's diverse clinical trial experience includes Phase I-IV trials and spans multiple therapeutic indications.
Hank graduated from the University of Florida with a B.A. in Economics.
Taylor Rice joined the Headlands Research team as the Director of Site Development. Taylor has over 7 years of clinical research experience with a comprehensive view of clinical site development. She possesses a strong aptitude for strategic clinical operations with a diligent focus on incorporating quality assurance. Prior to joining the Headlands team, she directed the Neurodegenerative Unit at Bioclinica. While at Bioclinica Taylor led the Neurodegenerative Unit to be recognized as one of the top Neurology Research Units in the world and consistently achieved top enroller status across multiple indications such as Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Lewy Body Dementia, and healthy Alzheimer’s prevention trials. Before Bioclinica she held multiple roles at Compass Research. Taylor will be focused on further developing current sites and will lead Headland’s upcoming de-novo CNS projects.
Taylor has a BS degree in Molecular and Microbiology from the University of Central Florida and lives in Orlando, Florida with her dogs Marly Mae and Ruby.
Emily Janvey, M.D. joined KKR in 2017 as a member of the Health Care industry team within KKR's Private Equity platform. Prior to joining KKR, Dr. Janvey invested with OrbiMed and spent over 4 years in TPG’s Special Situations group where she provided non-dilutive capital solutions to health care companies and institutions. Prior to investing, Dr. Janvey was a consultant at McKinsey and Company where she worked with large pharma and biotechs on M&A and growth strategy, and served major payers on pricing strategy and ACO development. She holds a B.A. in neuroscience, summa cum laude, from Hamilton College and an M.D. and M.B.A from The University of Pennsylvania’s Perelman School of Medicine and Wharton School respectively.
Ali J. Satvat joined KKR in 2012 and is a Member of KKR on the Health Care industry team within KKR’s Americas Private Equity platform. He leads KKR’s Health Care Strategic Growth investing efforts, sits on the Health Care Strategic Growth Investment Committee and is Chairman of the Health Care Strategic Growth Portfolio Management Committee. He currently serves on the boards of directors of AcuFocus, Arbor Pharmaceuticals, Blue Sprig Pediatrics, BridgeBio Pharma, Clarify Health Solutions, Cohera Medical, Coherus BioSciences, Eidos Therapeutics, Headlands Research, Impel NeuroPharma, Slayback Pharma, and Trilogy MedWaste and has been involved in KKR’s investments in Ajax Health, PRA Health Sciences, and Spirox. Previously, he held various positions with Apax Partners, Johnson & Johnson Development Corporation, Audax Group, and The Blackstone Group. Mr. Satvat holds an A.B., magna cum laude, in History and Science from Harvard College and an M.B.A. in Health Care Management and Entrepreneurial Management from the Wharton School of the University of Pennsylvania. He is a member of the board of directors of the Healthcare Private Equity Association.
Neel Varshney, MD (Menlo Park) joined KKR in 2016 and is a member of the Health Care team within KKR’s Americas Private Equity platform. He currently serves on the boards of directors of Ajax Health, Envision Healthcare, Headlands Research, BrightSpring PharMerica, and Slayback Pharma and was involved in KKR’s investment in Spirox. Dr. Varshney has been in the health care industry since 2002. He was vice president at Linden Capital Partners, serving on the board of directors of Corpak Medsystems before its sale to Halyard Health. He was an engagement manager at McKinsey & Company, working with private equity firms and corporations on acquisitions and strategy. Dr. Varshney also held a business development role at Medtronic. He earned a B.S. in Electrical Engineering with Honors from the University of Alabama at Birmingham and an M.D. with Honors from Harvard Medical School and Massachusetts Institute of Technology as a Soros Fellow. Dr. Varshney completed medical training at Massachusetts General Hospital and was a Rhodes Scholar at Oxford.
Dr. Roger Bullock completed his pre-clinical medical training at Keble College, Oxford University, gaining a BA (Hons) in Physiological Sciences in 1978 (converted to MA in 1985). This was followed by clinical medical training at St Bartholomew's Hospital in London where he gained the MB.BS in 1981.
In 1990, he specialized in psychiatry, gained membership of The Royal College of Psychiatry and undertook postgraduate psychiatric training including higher specialist training in geriatric psychiatry which concluded in 1993. Dr. Bullock is considered a world KOL in the space of neurodegenerative diseases. He has extensive experience as clinical researcher, having participated in more than 70 clinical trials in Alzheimer’s disease and other CNS conditions. Over his 30-year research career, he has authored and co-authored more than 100 peer-reviewed publications and book chapters in this domain and presented at numerous conferences. Recently he has been working as a consultant for companies active in the CNS space, including Lilly and Merck.
David Evans is CEO of Texas Neurology, among the largest and most comprehensive neurology practices in the country. He is extremely active in the American Academy of Neurology where he currently serves as Chair of the AAN’s Practice Management & Technology Subcommittee and is Past Chair of the Business section. He is also a member of the AAN’s Medical Economics & Management Committee and BrainPAC Executive Committee. Mr. Evans has extensive background in practice management consulting with emphasis in the implementation of ancillary services within physician practices.
Craig Lipset is a recognized leader at the forefront of innovation in clinical research and medicine development. He is an advisor to technology and biopharmaceutical companies, leading universities, and the venture community, bringing vision and driving action at the intersection of research, digital solutions, and patient engagement. Craig was the Head of Clinical Innovation and Venture Partner at Pfizer, on the founding Operations Committee for TransCelerate Biopharma, and on the founding management teams for two successful startup ventures (Perceptive Informatics and Adnexus Therapeutics).
During that time, Craig designed and launched multiple industry firsts -- from the first fully remote/virtual clinical trial for a new medicine to the first returning of results and data to research participants. He currently serves on the Board of Directors for the Foundation for Sarcoidosis Research, the MedStar Health Research Institute, and the People-Centered Research Foundation (the central office for PCORnet), as well as on the Editorial Board for Therapeutic Innovation & Regulatory Science. Craig has received the red jacket 'hall of fame' recognition among the PharmaVOICE most inspiring people in the life sciences. He has been recognized among Pharmaceutical Executive’s Emerging Leaders, CenterWatch Top 20 Innovators in Clinical Trials, the Medicine Maker Power List and the AlleyWatch Who's Who in eHealth. He studied Music at Brandeis University and earned a Master of Public Health from Columbia.
Jane Restorick is a recognized expert in site management, patient recruitment and clinical research operations. Prior to moving into consultancy, Jane was COO and Chief Patient Officer at Synexus Clinical Research, driving its growth from a UK based SMO to become a successful international operation across 11 countries. Previously she formed and led Operations and Quality Management teams at a virtual biopharma (Vanguard Medica) and at Fujisawa Early Clinical Evaluation Unit.
Steve Satek is the Founder and President of Great Lakes Clinical Trials. Steve has more than 30 years of experience in the clinical research industry. He began his career as a bench researcher at the Northwestern University Robert H. Lurie Cancer Center and since that time has held senior management positions at the Chicago Center for Clinical Research, Radiant Research, Cognitive Drug Research and Forenap Pharma.
Steve offers a diverse and thorough knowledge of clinical trial operations, which has been presented at over 25 industry conferences. In addition, he has personally project managed and/or coordinated over 150 trials. Steve currently serves as the Planning Committee Chairman for the Global Site Solutions Summit, one the clinical research industry's leading conferences.
Dr. Sharon Cohen is a behavioural neurologist known for her excellence in patient care, teaching, and clinical research. She completed her neurology residency and behavioural neurology fellowship at the University of Toronto. She is the medical director and site principal investigator of Toronto Memory Program, a community-based medical facility which she established in 1996 for the purpose of enhancing diagnosis, care, and therapeutic options for individuals with or at risk for Alzheimer’s disease and related disorders. Under her guidance, Toronto Memory Program’s multidisciplinary team has grown to a staff of 30 individuals. Its memory clinic and research site are among the most active in Canada.
Dr. Cohen has over 28 years of experience in clinical research and has been a site PI for over 100 pharmacological trials. She has participated in acute stroke trials as well as trials in FTD, PDD, DLB, HD, vascular dementia, and Alzheimer’s disease, the latter being her primary focus. Her site has been credited as a “go to” centre for Alzheimer’s trials and has been awarded for superior performance and quality in clinical research.
Dr. Cohen represents Canada on international advisory boards and steering committees and is a consultant to a wide range of stakeholders in dementia including government organizations and patient advocacy groups. She is a frequent lecturer and contributes to media events including those on medical ethics. She is known for her advocacy of individuals with neurodegenerative diseases.
Despite holding academic and hospital appointments, Dr. Cohen chooses to practice in the community, in keeping with her belief that dementia care and clinical research are best offered in the real world setting.
Dr. James Goldenberg is a Board-Certified Neurologist who practiced in Palm Beach County, Florida for 25 years. He currently serves as Sr. Vice President and Associate Medical Director of JEM Research Institute. Dr. Goldenberg cofounded the JEM Research Institute, a clinical research site that performs predominantly industry sponsored phase II – IV clinical trials to help develop new treatments in the area of neurology.
He previously served as Medical Director for Atlantic Coast Health Network, a regional super clinically integrated network (CIN), representing over 1,900 physicians and 200,000 lives in South Florida. In that role he is responsible for strategy, value-based care initiatives, population health and patient safety. His undergraduate training is in Psychology from the University of Florida. He received his Medical Degree from the University of South Florida. His neurology training and fellowship in neuromuscular disease were completed at the University of Miami.
Dr. Goldenberg has served JFK Hospital in Atlantis Florida in multiple leadership roles including Chairman of the Board of Trustees, Chairman of the Credentials Committee, Chairman of the Bylaws Committee, and Chief of the Department of Psychiatry and Neurology. He was the founding Medical Director of JFK Hospital’s stroke program and has helped develop their Comprehensive Stroke Center. Dr. Goldenberg has also served The Joint Commission as a disease-specific surveyor in stroke, the first physician to hold that position nationally. Dr. Goldenberg is an Affiliated Assistant Professor of Neurology at the Leonard M. Miller School of Medicine at the University of Miami. He has coordinated the Neurology rotation for second-year residents at JFK Hospital’s University of Miami sponsored Internal Medicine Residency program. He has also coordinated the Neurology medical student rotation for fourth-year medical students at the University of Miami’s Palm Beach Regional Campus.
Dr. Goldenberg is an advocate for patients and physicians at the local, regional, and national levels. He is a past president of the Palm Beach County Medical Society and currently serves on the Board of Directors. He is responsible for the development of the Physician Leadership Academy of South Florida. He has served the Florida Medical Association on the Board of Governors and the Council on Medical Economics and Practice Innovation. He is serving the American Academy of Neurology on the Board of Directors, Advocacy Committee, and chairs the Business Innovation Subcommittee. Through advocacy, education and the promotion of physician leadership training, he would like to help physicians prepare for the changing healthcare landscape.
Dr. Goldstein was born and raised in New York City. He graduated Colgate University, receiving a B.A. degree with a major in Biophysics. He obtained his MD degree from Emory University School of Medicine in Atlanta. Upon graduation, he completed residencies in both Internal Medicine (College of Medicine and Dentistry of New Jersey/Robert Wood Johnson) and Neurology (Stanford University). He is board certified in both Internal Medicine and Neurology. After relocating to South Florida, he joined a busy clinical neurology practice which he helped grow to 6 Neurologists.
Dr. Goldstein began participating in clinical trials in the late 1990’s. To date, he has participated in over 80 clinical trials, being the Principal Investigator 70 times. Most of these trials have been conducted through JEM Research Institute, of which he is a founding member and the CEO. Under his guidance, JEM has grown into a substantial clinical research site currently employing 26 people, and conducting over 20 active trials at any one time, many of which deal with progressive cognitive decline.
As a clinical neurologist, Dr. Goldstein serves as an Affiliated Assistant Clinical Professor of Neurology at the University of Miami. As a researcher, he is a Certified Principal Investigator as well as a Fellow of the Academy of Physicians in Clinical Research.
Dr. Goldstein has served on the board of directors of the Medical Specialists of The Palm Beaches, the largest multispecialty medical group in Palm Beach County. He has also been a member of the executive committee as well as chairman of the credentials committee at JFK Hospital in Atlantis. He has been both the Chief of the Division of Neurology and the Director of the Comprehensive Stroke Center at JFK.
Nathan Segall M.D. is a Certified Physician Investigator (CPI) and Principal Investigator and founder of Clinical Research Atlanta (CRA). He is well recognized in the pharmaceutical industry, successfully conducting over 400 (60+ vaccine) clinical trials since 1992 and authoring numerous articles and publications. Dr. Segall has practiced in the Atlanta area for more than 29 years. He is board certified in Internal Medicine as well as Pediatric and Adult Allergy & Immunology.